ORIGINAL ARTICLE

Article in PDF format - JOP Home page

JOP. J Pancreas (Online) 2005; 6(1):6-12.

Extracorporeal Shock Wave Lithotripsy in the Management of Chronic Calcific Pancreatitis: A Meta-Analysis

Nalini M Guda1, Susan Partington2, Martin L Freeman1

1Gastroenterology Division, Hennepin County Medical Center, University of Minnesota. Minneapolis, Minnesota, USA. 2Aurora Sinai Medical Center, University of Wisconsin Medical School, Milwaukee Clinical Campus. Milwaukee, Wisconsin, USA

ABSTRACT

Context Main pancreatic duct stones may contribute to pain in chronic pancreatitis. Extracorporeal shock wave lithotripsy (ESWL) has been used alone or in combination with endoscopic therapy for fragmentation of stones. Published studies have shown mixed efficacy due to small sample size.

Objective Systematic analysis of all published data evaluating ESWL with or without endoscopic therapy in pancreatic duct clearance and symptom relief.

Methods Two investigators independently reviewed the computer databases. 31 potential studies were identified. Only studies using ESWL with or without endoscopic therapy were included. Completeness of the search was confirmed by an expert. Studies were independently coded by two investigators and differences rectified by mutual consent.

Main outcome measures Pain at follow-up and duct clearance.

Results Seventeen studies published between 1989 and 2002 were included. Sixteen had a measure of pain at follow-up and duct clearance. All studies were case series with a total of 588 subjects, and included varying number of subjects undergoing endoscopic pancreatic sphincterotomy and stone extraction. The mean effect size (weighted correlation coefficient) for pain was 0.6215 and for duct clearance was 0.7432; thus indicating a large effect. All studies showed homogeneity suggesting similar effect size irrespective of the combinations of therapy.

Conclusions ESWL is effective in clearance of stones from the pancreatic duct and in relief of pain. Published studies showed homogeneity of the effect size of ESWL both in pancreatic duct clearance and relief of pain.


INTRODUCTION

Chronic pancreatitis is a clinical entity most often characterized by recurrent or persistent episodes of abdominal pain. There are many etiologies including alcohol, hereditary, and idiopathic [1]. Whether removal of the offending agent might positively alter the natural history of the disease in obstructive forms is still debated [2, 3, 4].

Presence of pancreatic calcifications is considered to be pathognomonic of chronic pancreatitis and can be seen in up to 90% of the patients with alcoholic pancreatitis at long term follow-up [5]. Pancreatic duct calculi are generally considered to be a consequence of chronic pancreatitis and not the cause [5, 6]. Pancreatic duct calculi can lead to outflow obstruction of the pancreatic zymogens with subsequent atrophy of the acinar cells and progressive fibrosis of the pancreatic gland. Outflow obstruction of the main pancreatic duct is thought to cause recurrent attacks of pancreatitis or chronic abdominal pain [7, 8]. Restitution of the pancreatic duct flow has shown to improve the physiological function of the pancreas [2, 3].

Pancreatic duct obstruction in chronic pancreatitis due to pancreatic duct calculi, strictures or both can be relieved by surgical techniques. However, these are invasive and are associated with significant morbidity and occasional mortality. Endoscopic drainage procedures including endoscopic pancreatic sphincterotomy, dilation of pancreatic strictures and the placement of pancreatic stents have been successfully performed [9, 10, 11, 12, 13]. These procedures are less invasive compared to surgery and carry a lower rates of morbidity. However, less than 70% of the stones can be removed by endoscopic techniques alone, and is most likely to be successful when the stone burden is small (3 or less stones, with a diameter less than or equal to 10 mm), and stones are confined to the head and or body of the pancreas. Presence of a downstream stricture or stone impaction are unfavorable for endoscopic drainage [14].

The problem of delivering a large stone through the pancreatic duct can potentially be overcome by reducing the stone size. There are limited data regarding chemical dissolution of pancreatic duct calculi. Mechanical lithotripsy using a through the scope mechanical lithotripter is technically challenging and successful only with few floating stones [15], while intraductal lithotripsy techniques are cumbersome and require highly specialized equipment. Fragmentation of pancreatic stones using extracorporeal shock wave lithotripsy (ESWL) serves as another alternative. Use of ESWL for gallstones was first reported by Sauerbruch et al. in Germany in 1987 [16], and has since been reported by several investigators for fragmentation of pancreatic stones [17, 18, 19, 20, 21, 22]. Data from these studies have been divergent. Most studies were observational in nature and included limited numbers of patients to evaluate the efficacy of ESWL on stone clearance and clinical outcomes. A meta-analysis of these published studies is hence performed to evaluate the heterogeneity and clinical outcomes with ESWL therapy for chronic calcific pancreatitis.

METHODS

Two investigators independently reviewed the computer databases Healthstar, MEDLINE and PreMEDLINE. Search words used were: "extracorporeal shockwave lithotripsy" and "chronic pancreatitis" or "pancreatic ducts" or "pancreatitis". Thirty potential studies were identified. Abstracts were reviewed and criteria used for inclusion were: i) ESWL as the only method of treatment or if treatment modalities were mixed, results were separated; ii) pancreatic ducts the only site treated or if treatment targets were mixed results were separated; iii) more than five cases reported in the study; and iv) some measure of pain at follow-up or duct clearance. In addition, an expert in the field reviewed the identified studies to make sure the search was complete.

Coding

Two investigators independently coded the studies and entered them into an Excel (Microsoft Co., Washington, DC, USA) spreadsheet. In addition to pain at follow-up and duct clearance potential moderators were coded; these included year of the study, country, age of subjects, gender, etiology of pancreatitis, presence of strictures, stent placement, length of follow-up, number of ESWL sessions, mean number of shockwaves, stone size, presence of multiple stones, type of lithotripter, and, finally, if sphincterotomy was performed. Findings were compared and disagreements in variable coding between the investigators were identified. Studies were reviewed again by each investigator and mutual agreement reached on appropriate coding. A large number of variables were included as possible modifiers when the articles were abstracted, so that this data would be available if needed. When the analysis was performed, it was determined that the studies were homogeneous with respect to the two outcomes: pain and duct clearance. Modifier analysis was not needed to explain lack of homogeneity, which is what they are used for in a meta-analysis.

STATISTICS

Two fixed effect model meta-analyses were conducted. One model was constructed on the effect of ESWL on pain at follow-up and one on the effect of ESWL on duct clearance. Statistical methods were based on those recommended by Cooper and Hedges [23]. The effect size is the degree of association between two variables. In this analysis it is the degree of association between ESWL treatment for chronic pancreatitis and pain at follow-up and duct clearance. The measure of effect for each study was converted into a correlation coefficient and this was used as the common metric for effect size. Values close to zero indicate very little effect and those larger and smaller than zero indicate a greater magnitude of effect size. A correlation coefficient of 0-0.10 indicates a small effect size, values ranging 0.11-0.30 indicate a medium effect size and values greater than 0.50 indicate a large effect size [24]. Any effect in between 0.31 and 0.50 may be considered medium to large using these numbers as a bench mark. The relationship can be either negative or positive. A standard error was computed for each measure. Correlation coefficients were weighted by the study size and a weighted average correlation coefficient was computed by combining correlation coefficients directly.

Homogeneity of effect size (Q) was computed to determine if the study effect sizes were uniform across all the studies. If the Q statistic exceeds the critical level of the chi square distribution at alpha equal to 0.05 it indicates the presence of variability that is due to factors other than sampling error. Outliers were detected by using a previously described procedure based on the Q statistic [25].

Since there are no validated tools to measure the relief of pain and to assess the duct clearance outcomes, data were coded as reported in the original work, and were highly varied. While most of them were dichotomous outcomes, others were rated using scales (as in last two pain items below). All were converted to effect size (r) in order to render them comparable.

Duct clearance:

Pain:

RESULTS

There were 17 studies included in the meta-analyses. These studies were performed between 1989 and 2002 and included diverse population across the globe. Six studies were from Germany, 4 from the United States, 2 from Japan and the remaining 5 from European countries other than Germany. The outcomes measured were variable. However, all studies included two major outcomes: duct clearance and pain relief. Sixteen studies had a measure of pain at follow-up and 16 studies had a measure of duct clearance, although one was excluded as an outlier. The Q statistic was not significant for pain (Q=11.38), while it was significant for duct clearance (it was 39.34 prior to eliminating the outlier and it was equal to 8.86 after eliminating the outlier); therefore, the effect size of one study was determined to be an outlier and excluded from further analysis [25]. Because the meta-analyses sets exhibited homogeneity of effect size when the outlier was removed from the analysis, moderator analysis was not conducted.

All of the studies were case reports and included a total of 588 subjects. The mean effect size for pain was 0.6215 (Table 1, Figure 1). The mean effect size for duct clearance was 0.7432 (Table 2, Figure 2). Available data indicate that both analyses exhibited homogeneity of effect size. Mean effect size measures for both the duct clearance and pain improvement indicate a large effect of EWSL, suggesting that ESWL is clinically useful in reducing the stone burden in the main pancreatic duct and also for improvement of pain. Since most studies included a combination of endoscopic therapies including pancreatic sphincterotomy, stent placement and endoscopic removal of the pancreatic stones following lithotripsy it is difficult to ascertain the individual role of endoscopic therapy. Data from this study also show a significant homogeneity which precludes us from performing any secondary analysis.

Table 1. Correlation coefficients effect of ESWL on pain at follow-up.

Study

Year

N pain

r pain (SE)

Sauerbruch [35]

1989

8

0.6149 (0.2351)

Den Toom [27]

1991

8

0.2500 (0.3543)

Sauerbruch [36]

1992

24

0.7179 (0.1011)

Delhaye [30]

1992

88

0.7208 (0.0515)

Schneider [37]

1994

39

0.7949 (0.0597)

Van der Hul [33]

1994

17

0.1764 (0.2422)

Wolf [22]

1995

9

0.7777 (0.1397)

Schreiber [38]

1996

10

0.4000 (0.2800)

Johanns [31]

1996

35

0.6571 (0.0974)

Ohara [32]

1996

32

0.7778 (0.0709)

Matthews [18]

1997

19

0.3684 (0.2037)

Costamagna [34]

1997

32

0.4375 (0.1452)

Adamek [25]

1999

80

0.5250 (0.0815)

Brand [29]

2000

38

0.6316 (0.0988)

Karasawa [39]

2002

24

0.5400 (0.1477)

Kozarek [17]

2002

28

0.8823 (0.0426)

Overall*

-

491

0.6215 (0.1716)

* df=15; Q=11.38

Figure 1. Effect size (r+SE) for measurement of effect of ESWL for pain relief. The solid line represents no effect and the dashed line the mean of effect size over all of the studies.

 

Table 2. Correlation coefficients effect of ESWL on duct clearance.

Study

Year

N duct

r duct (SE)

Sauerbruch [35]

1989

8

0.7500 (0.1654)

Den Toom [27]

1991

8

0.5000 (0.2835)

Sauerbruch [36]

1992

24

0.8506 (0.0576)

Delhaye [30]

1992

123

0.8049 (0.0319)

Schneider [37]

1994

48

0.7917 (0.0544)

Van der Hul [33]

1994

17

0.5294 (0.1799)

Wolf [22]

1995

12

0.8333 (0.0921)

Schreiber [38]

1996

10

0.6000 (0.2133)

Johanns [31]

1996

35

1.0000 (0.0000)

Ohara [32]

1996

32

0.7500 (0.0786)

Matthews [18]

1997

19

0.8948 (0.0470)

Costamagna [34]

1997

35

0.7143 (0.0840)

Brand [29]

2000

48

0.5000 (0.1094)

Karasawa [39]

2002

24

0.5800 (0.1384)

Rubenstein [20]

2002

23

0.6522 (0.1225)

Overall*

-

491

0.7432 (0.0175)

* df=14; Q=8.86

Figure 2. Effect size (r+SE) for measurement of effect of ESWL for duct clearance of pancreatic duct stones. The solid line represents no effect and the dashed line the mean of effect size over all of the studies.

 

DISCUSSION

In chronic calcific pancreatitis, the main goals of therapy have been to relieve pain by decompression of the main pancreatic duct, primarily by removing stones or treating strictures. Endoscopic decompression has been shown to be effective by some nonrandomized studies [11, 12, 26]. Endoscopic stone extraction and duct decompression is limited by the size of the pancreatic calculi and presence of strictures [14]. ESWL overcomes the problem of the stone size by fragmenting the stones and reducing the stone burden, thus facilitating endoscopic clearance of the duct. Though ESWL has been performed at various centers the results of clearance of the main pancreatic duct has ranged from 37.5% [27] to 100% [28]. Moreover, most studies have not shown any direct correlation between the stone fragmentation and duct clearance rates. Most patients with chronic pancreatitis complain of pain and this appears to be the most clinically important outcome, although a subjective outcome that is difficult to measure. The results of our meta-analysis indicate that ESWL has a significant impact on the improvement of pain, and that the effect of ESWL on pain relief is large. The potential mechanism for this improvement in pain is possibly due to main pancreatic duct decompression and relief of obstruction by stone fragmentation. Reasons for failure to relieve pain are many and may include incomplete stone clearance, persistent strictures, or parenchymal pancreatic pain due to a diseased organ and not related to ductal hypertension.

Although various studies have looked at a spectrum of other outcomes including improvement in the endocrine and exocrine function, weight gain etc., following clearance of the main pancreatic duct calculi [25, 29, 30, 31, 32] the outcome measures were inconsistent and data not sufficiently homogenous to allow meaningful interpretation.

In the studies reviewed, ESWL was tolerated well by patients, with no mortality, but some morbidity including pancreatitis [33], sepsis from biliary or pancreatic origin, pancreatic fluid collection, and gastric submucosal hematoma [34].

Outcomes of therapy are best studied in randomized, placebo controlled trials. Meta-analyses typically include data from randomized controlled trials to calculate the effect size. Unfortunately, there are no randomized trials of therapy for pancreatic duct stones. All reported literature is that of institutional experience based on case series. We have attempted to overcome this limitation by performing a two-way fixed model of meta-analysis and checking for the homogeneity of the studies included in this analysis.

In summary. this study is the first meta-analysis of the effect of ESWL on main pancreatic duct clearance and the relief of pain in patients with chronic calcific pancreatitis. Combining data from multiple centers may overcome the limitations of small case series from single centers with varied expertise. ESWL appears to be effective in both relief of main pancreatic duct obstruction and alleviation of pain in chronic calcific pancreatitis in combination with endoscopic therapy.

References

  1. Ammann RW, Akovbiantz A, Largiader F, Schueler G. Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. Gastroenterology 1984; 86:820-8. [More details]

  2. Greenlee HB, Prinz RA, Aranha GV. Long-term results of side-to-side pancreaticojejunostomy. World J Surg 1990; 14:70-6. [More details]

  3. Nealon WH, Townsend CM Jr, Thompson JC. Operative drainage of the pancreatic duct delays functional impairment in patients with chronic pancreatitis. A prospective analysis. Ann Surg 1988; 208:321-9. [More details]

  4. Steer ML. Classification and pathogenesis of pancreatitis. Surg Clin North Am 1989; 69:467-80. [More details]

  5. Ammann RW, Muench R, Otto R, Buehler H, Freiburghaus AU, Siegenthaler W. Evolution and regression of pancreatic calcification in chronic pancreatitis. A prospective long-term study of 107 patients. Gastroenterology 1988; 95:1018-28. [More details]

  6. Sarles H, Bernard JP, Gullo L. Pathogenesis of chronic pancreatitis. Gut 1990; 31:629-32. [More details]

  7. Ebbehoj N, Borly L, Bulow J, Rasmussen SG, Madsen P. Evaluation of pancreatic tissue fluid pressure and pain in chronic pancreatitis. A longitudinal study. Scand J Gastroenterol 1990; 25:462-6. [More details]

  8. Widdison AL, Alvarez C, Karanjia ND, Reber HA. Experimental evidence of beneficial effects of ductal decompression in chronic pancreatitis. Endoscopy 1991; 23:151-4. [More details]

  9. Cremer M, Deviere J, Delhaye M, Vandermeeren A, Baize M. Endoscopic management of chronic pancreatitis. Acta Gastroenterol Belg 1993; 56:192-200. [More details]

  10. Fuji T, Amano H, Harima K, Aibe T, Asagami F, Kinukawa K, et al. Pancreatic sphincterotomy and pancreatic endoprosthesis. Endoscopy 1985; 17:69-72. [More details]

  11. Huibregtse K, Schneider B, Vrij AA, Tytgat GN. Endoscopic pancreatic drainage in chronic pancreatitis. Gastrointest Endosc 1988; 34:9-15. [More details]

  12. Kozarek RA, Patterson DJ, Ball TJ, Traverso LW. Endoscopic placement of pancreatic stents and drains in the management of pancreatitis. Ann Surg 1989; 209:261-6. [More details]

  13. McCarthy J, Geenen JE, Hogan WJ. Preliminary experience with endoscopic stent placement in benign pancreatic diseases. Gastrointest Endosc 1988; 34:16-18. [More details]

  14. Sherman S, Lehman GA, Hawes RH, Ponich T, Miller LS, Cohen LB, et al. Pancreatic ductal stones: frequency of successful endoscopic removal and improvement in symptoms. Gastrointest Endosc 1991; 37:511-7. [More details]

  15. Freeman ML. Mechanical lithotripsy of pancreatic duct stones. Gastrointest Endosc 1996; 44:333-6. [More details]

  16. Sauerbruch T, Holl J, Sackmann M, Werner R, Wotzka R, Paumgartner G. Disintegration of a pancreatic duct stone with extracorporeal shock waves in a patient with chronic pancreatitis. Endoscopy 1987; 19:207-8. [More details]

  17. Kozarek RA, Brandabur JJ, Ball TJ, Gluck M, Patterson DJ, Attia F, et al. Clinical outcomes in patients who undergo extracorporeal shock wave lithotripsy for chronic calcific pancreatitis. Gastrointest Endosc 2002; 56:496-500. [More details]

  18. Matthews K, Correa RJ, Gibbons RP, Weissman RM, Kozarek RA. Extracorporeal shock wave lithotripsy for obstructing pancreatic duct calculi. J Urol 1997; 158:522-5. [More details]

  19. Rawat B, Fache JS, Burhenne HJ. Extracorporeal shockwave lithotripsy of pancreatic duct stones. Gastrointest Radiol 1992; 17:145-7. [More details]

  20. Rubenstein JN, Parsons WG, Kim SC, Weiser AC, Loor MM, Kube DS, Nadler RB. Extracorporeal shock wave lithotripsy of pancreatic duct stones using the Healthtronics LithoTron lithotriptor and the Dornier HM3 lithotripsy machine. J Urol 2002; 167(2 Pt 1):485-7. [More details]

  21. Wolf JS Jr, Stoller ML. Application of urologic techniques to nonurinary calculi. Urology 1990; 36:383-9. [More details]

  22. Wolf JS Jr, Nakada SY, Aliperti G, Edmundowicz SA, Clayman RV. Washington University experience with extracorporeal shock-wave lithotripsy of pancreatic duct calculi. Urology 1995; 46:638-42. [More details]

  23. Cooper H, Hedges L. The Handbook of Research Synthesis. New York, NY, USA: Russel Sage Foundation, 1994. [More details]

  24. Cohen J. A power primer. Psychol Bull 1992; 112:155-9. [More details]

  25. Adamek HE, Jakobs R, Buttmann A, Adamek MU, Schneider AR, Riemann JF. Long term follow up of patients with chronic pancreatitis and pancreatic stones treated with extracorporeal shock wave lithotripsy. Gut 1999; 45:402-5. [More details]

  26. Cremer M, Deviere J, Delhaye M, Vandermeeren A, Baize M. Non-surgical management of severe chronic pancreatitis. Scand J Gastroenterol Suppl 1990; 175:77-84. [More details]

  27. Den Toom R, Nijs HG, van Blankenstein M, Schroder FH, Jeekel J, Terpstra OT. Extracorporeal shock wave lithotripsy of pancreatic duct stones. Am J Gastroenterol 1991; 86:1033-6. [More details]

  28. Soehendra N, Grimm H, Meyer HW, Schreiber HW. Extracorporeal shockwave lithotripsy in chronic pancreatitis. Dtsch Med Wochenschr 1989; 114:1402-6. [More details]

  29. Brand B, Kahl M, Sidhu S, Nam VC, Sriram PV, Jaeckle S, et al. Prospective evaluation of morphology, function, and quality of life after extracorporeal shockwave lithotripsy and endoscopic treatment of chronic calcific pancreatitis. Am J Gastroenterol 2000; 95:3428-8. [More details]

  30. Delhaye M, Vandermeeren A, Baize M, Cremer M. Extracorporeal shock-wave lithotripsy of pancreatic calculi. Gastroenterology 1992; 102:610-20. [More details]

  31. Johanns W, Jakobeit C, Greiner L, Janssen J. Ultrasound-guided extracorporeal shock wave lithotripsy of pancreatic ductal stones: six years' experience. Can J Gastroenterol 1996; 10:471-5. [More details]

  32. Ohara H, Hoshino M, Hayakawa T, Kamiya Y, Miyaji M, Takeuchi T, et al. Single application extracorporeal shock wave lithotripsy is the first choice for patients with pancreatic duct stones. Am J Gastroenterol 1996; 91:1388-94. [More details]

  33. van der Hul R, Plaisier P, Jeekel J, Terpstra O, den Toom R, Bruining H. Extracorporeal shock-wave lithotripsy of pancreatic duct stones: immediate and long-term results. Endoscopy 1994; 26:573-8. [More details]

  34. Costamagna G, Gabbrielli A, Mutignani M, Perri V, Pandolfi M, Boscaini M, Crucitti F. Extracorporeal shock wave lithotripsy of pancreatic stones in chronic pancreatitis: immediate and medium-term results. Gastrointest Endosc 1997; 46:231-6. [More details]

  35. Sauerbruch T, Holl J, Sackmann M, Paumgartner G. Extracorporeal shock wave lithotripsy of pancreatic stones. Gut 1989; 30:1406-11. [More details]

  36. Sauerbruch T, Holl J, Sackmann M, Paumgartner G. Extracorporeal lithotripsy of pancreatic stones in patients with chronic pancreatitis and pain: a prospective follow up study. Gut 1992; 33:969-72. [More details]

  37. Schneider HT, May A, Benninger J, Rabenstein T, Hahn EG, Katalinic A, Ell C. Piezoelectric shock wave lithotripsy of pancreatic duct stones. Am J Gastroenterol 1994; 89:2042-8. [More details]

  38. Schreiber F, Gurakuqi GC, Pristautz H, Trauner M, Schnedl W. Sonographically-guided extracorporeal shockwave lithotripsy for pancreatic stones in patients with chronic pancreatitis. J Gastroenterol Hepatol 1996; 11:247-51. [More details]

  39. Karasawa Y, Kawa S, Aoki Y, Ochi Y, Unno H, Kiyosawa K, Watanabe T. Extracorporeal shock wave lithotripsy of pancreatic duct stones and patient factors related to stone disintegration. J Gastroenterol 2002; 37:369-75. [More details]

Full text: PDF format
  Look up who cited this article

Received September 13th, 2004 - Accepted October 18th, 2004

Keywords Endoscopy; Lithotripsy; Pancreatitis

Abbreviations ESWL: extracorporeal shock wave lithotripsy

Correspondence
Martin L Freeman
Gastroenterology Division
University of Minnesota
Hennepin County Medical Center
701 Park Avenue
Minneapolis, MN 55415
USA
Phone: +1-612.347.8582
Fax: +1-612.904.4366
E-mail: freem020@umn.edu

JOP Home page